ZAMBA: Zoledronic Acid for Modic Back Pain. A randomized, double blind, placebo-controlled, multicenter trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517345-14-00

Acronym

ZAMBA

Enrollment

118

Registered

2025-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

Change from baseline at one year in mean Oswestry Disability Index (ODI)-score

Detailed description

Change from baseline at one year in mean LBP intensity (three NRS scales), Change from baseline at one year in Roland Morris Disability Questionnaire (RMDQ) score, Change from baseline at one year in EQ-5D, Concomitant treatments (pharm. and non-pharmacological) used between baseline and one-year follow-up, Global perceived effect at one year follow-up

Interventions

DRUGNaCl 0

DRUG9 % B. Braun

DRUGsolution pour perfusion

DRUGAclasta 5 mg solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline at one year in mean Oswestry Disability Index (ODI)-score	—

Secondary

Measure	Time frame
Change from baseline at one year in mean LBP intensity (three NRS scales), Change from baseline at one year in Roland Morris Disability Questionnaire (RMDQ) score, Change from baseline at one year in EQ-5D, Concomitant treatments (pharm. and non-pharmacological) used between baseline and one-year follow-up, Global perceived effect at one year follow-up	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026